NASDAQ:CNMD - CONMED Stock Price, Price Target & More

Get Started

$68.38 -0.04 (-0.06 %)

(As of 05/27/2018 03:55 PM ET)

Previous Close$68.38

Today's Range$68.02 - $68.98

52-Week Range$47.41 - $69.55

Volume63,840 shs

Average Volume160,052 shs

Market Capitalization$1.92 billion

P/E Ratio33.36

Dividend Yield1.17%

Beta0.6

About CONMED (NASDAQ:CNMD)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company's products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:CNMD

CUSIP20741010

Webwww.conmed.com

Phone315-797-8375

Debt

Debt-to-Equity Ratio0.69

Current Ratio2.15

Quick Ratio1.23

Price-To-Earnings

Trailing P/E Ratio33.36

Forward P/E Ratio31.51

P/E Growth2.74

Sales & Book Value

Annual Sales$796.39 million

Price / Sales2.41

Cash Flow$4.0035 per share

Price / Cash17.08

Book Value$22.92 per share

Price / Book2.98

Profitability

EPS (Most Recent Fiscal Year)$1.89

Net Income$55.48 million

Net Margins8.71%

Return on Equity9.46%

Return on Assets4.28%

Miscellaneous

Employees3,100

Outstanding Shares28,040,000

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Thursday, May 24th. Stockholders of record on Friday, June 15th will be given a dividend of $0.20 per share on Thursday, July 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, June 14th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) released its quarterly earnings data on Wednesday, April, 25th. The medical technology company reported $0.53 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.43 by $0.10. The medical technology company had revenue of $202.10 million for the quarter, compared to analyst estimates of $196.51 million. CONMED had a net margin of 8.71% and a return on equity of 9.46%. The firm's quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.38 earnings per share. View CONMED's Earnings History.

When is CONMED's next earnings date?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $2.15-$2.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.14.

What price target have analysts set for CNMD?

3 Wall Street analysts have issued twelve-month target prices for CONMED's stock. Their forecasts range from $46.00 to $73.00. On average, they anticipate CONMED's share price to reach $59.50 in the next twelve months. View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:

1. According to Zacks Investment Research, "CONMED exited the first quarter of 2018 with strong top-line growth and margin expansion. Strong performances by Advanced Surgical and Endoscopic Technologies buoy optimism. We are also upbeat about the continued innovation undertaken by the company over the last year. Solid revenue guidance is indicative of brighter prospects. CONMED is also benefiting from the increasing trend of using minimally invasive techniques as a large percentage of the company’s products are designed for these procedures. CONMED outperformed the industry in a year’s time. CONMED operates in a highly competitive environment, especially in the General Surgery business. Lower healthcare spending buoyed by the foreign exchange volatility is a headwind. Moreover, CONMED’s stock looks much overvalued at the moment. Pricing pressures add to the woes. Long-term debt at the end of the just-reported first quarter was also high, raising concerns." (4/27/2018)
2. Needham & Company LLC analysts commented, "We hosted investor meetings in Boston with CNMD’s CEO and CFO earlier this week. We believe that CNMD is making progress in its turnaround, as evidenced by its organic revenue growth of 3% year-to-date (YTD), which is a considerable improvement from the bottom of (3%) growth in 2H14. We expect further improvement in its domestic Orthopedic Surgery business as new products continue to gain momentum and believe that this can push overall revenue growth towards 5%. We also believe that margin expansion will be the next chapter in the CNMD story given higher revenue growth, a reduced currency headwind, and a renewed focus on cost reductions. CNMD’s operating margin is currently around 9% and we see potential for this to reach the mid-teens or higher over time. We think the stock looks undervalued at a P/E of 25.5x our 2018E estimate considering that we think its potential earnings power is $3.00+ per share and we reiterate our Buy rating." (11/17/2017)

Who are some of CONMED's key competitors?

Some companies that are related to CONMED include Masimo (MASI), LivaNova (LIVN), Getinge Group (GNGBY), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Biolife Solutions (BLFS) and Zynex (ZYXI).

Who are CONMED's key executives?

CONMED's management team includes the folowing people:

Mr. Curt R. Hartman, CEO, Pres & Director (Age 54)
Mr. Patrick J. Beyer, Pres of CONMED International (Age 52)
Mr. Luke A. Pomilio, Advisor to Chief Financial Officer (Age 53)
Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 43)
Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 43)

Has CONMED been receiving favorable news coverage?

News articles about CNMD stock have been trending somewhat positive on Sunday, according to Accern. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CONMED earned a coverage optimism score of 0.08 on Accern's scale. They also gave media coverage about the medical technology company an impact score of 46.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are CONMED's major shareholders?

CONMED's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.69%), Scopia Capital Management LP (7.75%), Dimensional Fund Advisors LP (7.40%), Victory Capital Management Inc. (6.46%), Champlain Investment Partners LLC (4.72%) and Northern Trust Corp (2.22%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert and Terence M Berge. View Institutional Ownership Trends for CONMED.

Which major investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Victory Capital Management Inc., Champlain Investment Partners LLC, Dimensional Fund Advisors LP, Thrivent Financial for Lutherans, Westwood Holdings Group Inc., Citadel Advisors LLC and Lord Abbett & CO. LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, Jo Ann Golden, Luke A Pomilio, Nathan Folkert and Terence M Berge. View Insider Buying and Selling for CONMED.

Which major investors are buying CONMED stock?

CNMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., WINTON GROUP Ltd, Prudential Financial Inc., Hsbc Holdings PLC, Prescott Group Capital Management L.L.C., Epoch Investment Partners Inc., Summit Global Investments and A.R.T. Advisors LLC. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $68.38.

How big of a company is CONMED?

CONMED has a market capitalization of $1.92 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.

MarketBeat Community Rating for CONMED (CNMD)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		258 (Vote Outperform)
Underperform Votes:		194 (Vote Underperform)
Total Votes:		452

MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

CONMED (NASDAQ:CNMD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for CONMED in the last 12 months. Their average twelve-month price target is $59.50, suggesting that the stock has a possible downside of 12.99%. The high price target for CNMD is $73.00 and the low price target for CNMD is $46.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.33	2.25	2.25	2.25
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$59.50	$55.6667	$55.00	$50.6667
Price Target Upside:	12.99% downside	11.79% downside	4.81% downside	2.41% downside

CONMED (NASDAQ:CNMD) Consensus Price Target History

Price Target History for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/26/2018	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$71.00 ➝ $73.00	High
11/3/2017	KeyCorp	Reiterated Rating	Hold		N/A
11/3/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$46.00	N/A
4/27/2017	Ladenburg Thalmann	Downgrade	Buy ➝ Neutral	$50.00 ➝ $48.00	High
11/23/2016	Leerink Swann	Reiterated Rating	Hold ➝ Neutral		N/A

(Data available from 5/27/2016 forward)

CONMED (NASDAQ:CNMD) Earnings History and Estimates Chart

Earnings by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Earnings Estimates

2018 EPS Consensus Estimate: $2.07
2019 EPS Consensus Estimate: $2.42

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.42	$0.43	$0.43
Q2 2018	3	$0.45	$0.46	$0.45
Q3 2018	3	$0.41	$0.48	$0.45
Q4 2018	3	$0.72	$0.78	$0.74
Q1 2019	1	$0.49	$0.49	$0.49
Q2 2019	1	$0.54	$0.54	$0.54
Q3 2019	1	$0.55	$0.55	$0.55
Q4 2019	1	$0.84	$0.84	$0.84

CONMED (NASDAQ CNMD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/24/2018		$0.45					N/A
4/25/2018	Q1 2018	$0.43	$0.53	$196.51 million	$202.10 million	View	N/A
1/31/2018	Q4 2017	$0.65	$0.69	$212.17 million	$222.60 million	View	N/A
11/2/2017	Q3 2017	$0.41	$0.42	$187.13 million	$190.10 million	View	N/A
7/26/2017	Q2 2017	$0.41	$0.41	$194.50 million	$197.20 million	View	N/A
4/26/2017	Q1 2017	$0.35	$0.38	$181.47 million	$186.57 million	View	N/A
2/1/2017	Q416	$0.56	$0.54	$204.04 million	$204.10 million	View	Listen
10/27/2016	Q316	$0.41	$0.41	$180.13 million	$184.79 million	View	Listen
7/27/2016	Q216	$0.46	$0.47	$191.48 million	$193.40 million	View	Listen
4/27/2016	Q116	$0.41	$0.42	$180.15 million	$181.20 million	View	Listen
1/27/2016	Q415	$0.51	$0.52	$191.03 million	$191.00 million	View	Listen
10/21/2015	Q315	$0.44	$0.38	$173.96 million	$169.20 million	View	Listen
7/21/2015	Q215	$0.44	$0.36	$182.40 million	$181.00 million	View	Listen
4/22/2015	Q115	$0.41	$0.42	$176.16 million	$177.90 million	View	Listen
1/27/2015	Q414	$0.54	$0.53	$196.00 million	$195.00 million	View	Listen
10/23/2014	Q314	$0.39	$0.44	$173.30 million	$175.00 million	View	Listen
7/23/2014	Q214	$0.47	$0.47	$190.62 million	$188.20 million	View	Listen
4/24/2014	Q1	$0.47	$0.49	$191.95 million	$181.90 million	View	Listen
2/13/2014	Q413	$0.49	$0.53	$197.24 million	$203.40 million	View	Listen
10/24/2013	Q313	$0.40	$0.40	$186.20 million	$179.30 million	View	Listen
7/24/2013	Q2 2013	$0.44	$0.43	$193.55 million	$193.00 million	View	Listen
4/25/2013	Q1 2013	$0.45	$0.45	$196.79 million	$187.00 million	View	Listen
2/14/2013	Q4 2012	$0.50	$0.52	$200.12 million	$201.20 million	View	Listen
10/25/2012		$0.40	$0.43			View	N/A
7/26/2012		$0.45	$0.43			View	N/A
4/26/2012		$0.44	$0.43			View	N/A
2/15/2012		$0.39	$0.46			View	N/A
10/27/2011		$0.31	$0.33			View	N/A
7/28/2011		$0.35	$0.35			View	N/A
4/28/2011		$0.31	$0.37			View	N/A
2/3/2011		$0.36	$0.36			View	N/A
10/28/2010	Q3 2010	$0.28	$0.34			View	N/A
7/29/2010	Q2 2010	$0.26	$0.32			View	N/A
4/29/2010	Q1 2010	$0.26	$0.28			View	N/A
2/4/2010	Q4 2009	$0.32	$0.37			View	N/A
10/22/2009	Q3 2009	$0.17	$0.28			View	N/A
7/30/2009	Q2 2009	$0.16	$0.17			View	N/A
4/23/2009	Q1 2009	$0.24	$0.19			View	N/A
2/5/2009	Q4 2008	$0.30	$0.34			View	N/A
10/23/2008	Q3 2008	$0.34	$0.37			View	N/A
7/24/2008	Q2 2008	$0.39	$0.43			View	N/A
4/24/2008	Q1 2008	$0.35	$0.38			View	N/A
2/7/2008	Q4 2007	$0.38	$0.44			View	N/A

(Earnings results data provided by Zacks Investment Research)

CONMED (NASDAQ:CNMD) Dividend Information

CONMED pays an annual dividend of $0.80 per share, with a dividend yield of 1.17%. CNMD's next quarterly dividend payment will be made on Thursday, July 5. CONMED pays out 42.33% of its earnings out as a dividend.

Next Dividend:	7/5/2018
Annual Dividend:	$0.80
Dividend Yield:	1.17%
Payout Ratio(s):	42.33% (Trailing 12 Months of Earnings) 36.87% (Based on This Year's Estimates) 33.20% (Based on Next Year's Estimates) 19.98% (Based on Cash Flow)

Dividend Payments by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/24/2018	quarterly	$0.20	1.17%	6/14/2018	6/15/2018	7/5/2018
2/28/2018	quarterly	$0.20	1.31169044105591%	3/14/2018	3/15/2018	4/5/2018
11/28/2017	quarterly	$0.20	1.48%	12/14/2017	12/15/2017	1/5/2018
8/29/2017	quarterly	$0.20	1.65%	9/14/2017	9/15/2017	10/5/2017
5/24/2017	quarterly	$0.20	1.6%	6/13/2017	6/15/2017	7/5/2017
2/28/2017	quarterly	$0.20	1.92%	3/13/2017	3/15/2017	4/5/2017
11/21/2016	quarterly	$0.20	1.77%	12/13/2016	12/15/2016	1/5/2017
8/25/2016	quarterly	$0.20	1.99%	9/13/2016	9/15/2016	10/5/2016
5/25/2016	quarterly	$0.20	2.05%	6/13/2016	6/15/2016	7/6/2016
2/23/2016	quarterly	$0.20	2.1%	3/11/2016	3/15/2016	4/5/2016
11/16/2015	quarterly	$0.20	1.92%	12/11/2015	12/15/2015	1/5/2016
8/24/2015	quarterly	$0.20	1.53%	9/11/2015	9/15/2015	10/5/2015
5/29/2015	quarterly	$0.20	1.44%	6/11/2015	6/15/2015	7/6/2015
2/25/2015	quarterly	$0.20	1.56%	3/12/2015	3/16/2015	4/6/2015
11/18/2014	quarterly	$0.20	1.92%	12/11/2014	12/15/2014	1/5/2015
8/25/2014	quarterly	$0.20	2.11%	9/11/2014	9/15/2014	10/6/2014
5/23/2014	quarterly	$0.20	1.8%	6/12/2014	6/16/2014	7/7/2014
2/27/2014	quarterly	$0.20	1.72%	3/13/2014	3/17/2014	4/7/2014
10/28/2013	quarterly	$0.20		12/12/2013	12/16/2013	1/6/2014
8/27/2013	quarterly	$0.15	1.91%	9/12/2013	9/16/2013	10/4/2013
5/24/2013	quarterly	$0.15	1.76%	6/13/2013	6/17/2013	7/8/2013
2/27/2013	quarterly	$0.15	1.93%	3/13/2013	3/15/2013	4/5/2013

(Data available from 1/1/2013 forward)

CONMED (NASDAQ CNMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.13%
Institutional Ownership Percentage: 95.19%

Insider Trading History for CONMED (NASDAQ:CNMD)

Institutional Ownership by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ CNMD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2018	Jo Ann Golden	Director	Sell	3,000	$67.62	$202,860.00	7,782
5/7/2018	Jo Ann Golden	Director	Sell	3,000	$67.23	$201,690.00	10,782
4/27/2018	Daniel Jonas	EVP	Sell	2,000	$65.58	$131,160.00	23,245
4/27/2018	Jo Ann Golden	Director	Sell	5,698	$65.40	$372,649.20	19,480
4/27/2018	Nathan Folkert	VP	Sell	4,409	$64.98	$286,496.82	1,264
3/9/2018	Terence M Berge	VP	Sell	3,868	$62.45	$241,556.60	19,908
3/1/2018	Luke A Pomilio	CFO	Sell	19,620	$60.19	$1,180,927.80	600
2/12/2018	Luke A. Pomilio	CFO	Sell	1,962	$60.25	$118,210.50
2/1/2018	Jo Ann Golden	Director	Sell	3,000	$63.90	$191,700.00
2/1/2018	Luke A. Pomilio	CFO	Sell	18,023	$63.38	$1,142,297.74
1/3/2018	Charles Farkas	Director	Buy	158	$50.61	$7,996.38	11,707
11/9/2017	Luke A Pomilio	EVP	Sell	29,363	$50.70	$1,488,704.10	45,486
11/7/2017	Luke A Pomilio	CFO	Sell	12,429	$50.63	$629,280.27	45,486
11/3/2017	Luke A Pomilio	EVP	Sell	10,020	$53.57	$536,771.40	44,472
10/3/2017	Charles Farkas	Director	Buy	148	$53.96	$7,986.08	11,549
8/14/2017	Jo Ann Golden	Director	Sell	3,000	$50.00	$150,000.00	19,782
7/5/2017	Charles Farkas	Director	Buy	157	$50.78	$7,972.46	11,401
6/13/2017	Dirk Kuyper	Director	Sell	1,000	$52.24	$52,240.00	10,739
5/15/2017	Daniel Jonas	EVP	Sell	3,000	$51.22	$153,660.00	14,455
4/3/2017	Charles Farkas	Director	Buy	180	$44.41	$7,993.80	8,505
3/13/2017	Heather L Cohen	EVP	Buy	440	$40.00	$17,600.00	11,291
3/10/2017	Curt R Hartman	CEO	Buy	8,030	$40.11	$322,083.30	36,470
3/6/2017	Mark E Tryniski	Director	Buy	5,000	$41.15	$205,750.00	27,000
1/3/2017	Charles Farkas	Director	Buy	305	$44.65	$13,618.25	8,325
11/8/2016	Daniel Jonas	EVP	Sell	1,500	$41.78	$62,670.00	16,590
11/7/2016	Daniel Jonas	EVP	Sell	2,555	$40.40	$103,222.00	20,120
10/3/2016	Charles Farkas	Director	Buy	336	$40.04	$13,453.44	8,020
7/1/2016	Charles Farkas	Director	Buy	282	$47.87	$13,499.34	7,684
6/3/2016	Luke A Pomilio	CFO	Sell	4,400	$41.56	$182,864.00	41,884
4/1/2016	Charles Farkas	Director	Buy	338	$42.04	$14,209.52	4,399
3/4/2016	Mark D Snyder	EVP	Sell	2,940	$41.32	$121,480.80	14,262
3/2/2016	John L Workman	Director	Buy	2,500	$39.85	$99,625.00	4,500
2/19/2016	Jerome J Lande	Director	Sell	1,630,800	$38.28	$62,427,024.00	4,000
1/4/2016	Charles Farkas	Director	Buy	332	$42.18	$14,003.76	4,064
12/11/2015	David M Bronson	Director	Buy	1,500	$41.01	$61,515.00	1,500
6/12/2015	Jo Ann Golden	Director	Sell	1,000	$56.03	$56,030.00
5/29/2015	Stephen Mandia	Director	Sell	14,000	$55.62	$778,680.00
5/6/2015	Pat Beyer	Insider	Buy	5,000	$53.36	$266,800.00
4/30/2015	Stephen Mandia	Director	Sell	3,899	$49.97	$194,833.03
12/12/2014	Stephen Mandia	Director	Sell	4,500	$43.23	$194,535.00
12/1/2014	Dirk Kuyper	Director	Sell	1,000	$42.85	$42,850.00
11/19/2014	Joseph G Darling	EVP	Sell	4,270	$42.00	$179,340.00
10/29/2014	Robert D Shallish Jr	CFO	Sell	10,410	$41.67	$433,784.70
9/4/2014	William Abraham	EVP	Sell	16,062	$39.91	$641,034.42
8/26/2014	William Abraham	EVP	Sell	7,423	$38.36	$284,746.28
8/21/2014	William Abraham	EVP	Sell	15,986	$37.71	$602,832.06
8/19/2014	William Abraham	EVP	Sell	5,312	$37.75	$200,528.00
7/31/2014	Curt R Hartman	CEO	Buy	10,000	$39.25	$392,500.00
7/30/2014	Bruce Daniels	Director	Sell	1,600	$39.31	$62,896.00
7/30/2014	Joseph J Corasanti	CEO	Sell	109,035	$39.25	$4,279,623.75
10/29/2013	Joseph J Corasanti	CEO	Sell	80,148	$36.47	$2,922,997.56
10/28/2013	Bruce Daniels	Director	Sell	4,500	$36.43	$163,935.00
9/13/2013	Joseph Corasanti	CEO	Sell	44,852	$33.04	$1,481,910.08	114,148
9/11/2013	William Abraham	SVP	Sell	7,423	$33.48	$248,522.04	21,659
8/15/2013	Dirk Kuyper	Director	Buy	1,000	$31.63	$31,630.00	1,000
6/7/2013	Daniel Jonas	VP	Sell	2,000	$32.42	$64,840.00
6/4/2013	Heather L Cohen	VP	Sell	1,200	$32.59	$39,108.00
5/31/2013	Luke A Pomilio	VP	Sell	2,556	$33.19	$84,833.64
5/29/2013	Heather L Cohen	VP	Sell	4,514	$34.31	$154,875.34
5/28/2013	Robert D Shallish Jr	CFO	Sell	10,000	$34.35	$343,500.00
2/15/2013	Stuart J Schwartz	Director	Sell	1,000	$30.32	$30,320.00

(Data available from 1/1/2013 forward)

CONMED (NASDAQ CNMD) News Headlines

Source:

Date	Headline
	CONMED (CNMD) Up 9.1% Since Earnings Report: Can It Continue? finance.yahoo.com - May 25 at 4:18 PM
	CONMED Co. Plans Quarterly Dividend of $0.20 (CNMD) www.americanbankingnews.com - May 24 at 4:43 PM
	CONMED Co. (CNMD) Expected to Post Quarterly Sales of $207.13 Million www.americanbankingnews.com - May 22 at 2:34 AM
	Zacks: Analysts Expect CONMED Co. (CNMD) to Announce $0.45 Earnings Per Share www.americanbankingnews.com - May 20 at 5:14 PM
	Global Surgical Stapling Devices Market Growth Opportunities: Conmed Corporation, Medtronic Inc www.marketwatch.com - May 16 at 10:04 AM
	CONMED Co. (CNMD) Director Sells $202,860.00 in Stock www.americanbankingnews.com - May 11 at 1:22 PM
	CONMED Co. (CNMD) Director Sells $201,690.00 in Stock www.americanbankingnews.com - May 8 at 1:17 PM
	CONMED Co. (CNMD) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - May 7 at 9:05 AM
	Brokerages Expect CONMED Co. (CNMD) Will Post Quarterly Sales of $207.13 Million www.americanbankingnews.com - May 5 at 4:21 AM
	CONMED (CNMD) Upgraded to "Strong-Buy" at BidaskClub www.americanbankingnews.com - May 5 at 12:29 AM
	$0.45 Earnings Per Share Expected for CONMED Co. (CNMD) This Quarter www.americanbankingnews.com - May 3 at 10:17 AM
	Analyzing CONMED (CNMD) & Edap Tms (EDAP) www.americanbankingnews.com - May 2 at 5:44 PM
	Daniel Jonas Sells 2,000 Shares of CONMED Co. (CNMD) Stock www.americanbankingnews.com - April 30 at 4:14 PM
	CONMED Co. (CNMD) VP Nathan Folkert Sells 4,409 Shares www.americanbankingnews.com - April 30 at 4:14 PM
	CONMED Co. (CNMD) Director Jo Ann Golden Sells 5,698 Shares www.americanbankingnews.com - April 30 at 4:14 PM
	CONMED Co. to Post Q4 2018 Earnings of $0.72 Per Share, Leerink Swann Forecasts (CNMD) www.americanbankingnews.com - April 30 at 4:18 AM
	CONMED (CNMD) Lifted to Hold at Zacks Investment Research www.americanbankingnews.com - April 27 at 12:44 PM
	FY2018 Earnings Estimate for CONMED Co. (CNMD) Issued By Leerink Swann www.americanbankingnews.com - April 27 at 9:34 AM
	KeyCorp Research Analysts Lower Earnings Estimates for CONMED Co. (CNMD) www.americanbankingnews.com - April 27 at 7:58 AM
	Piper Jaffray Comments on CONMED Co.'s Q2 2018 Earnings (CNMD) www.americanbankingnews.com - April 27 at 7:58 AM
	CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance finance.yahoo.com - April 26 at 4:12 PM
	Edited Transcript of CNMD earnings conference call or presentation 25-Apr-18 8:30pm GMT finance.yahoo.com - April 26 at 4:12 PM
	Needham & Company LLC Boosts CONMED (CNMD) Price Target to $73.00 www.americanbankingnews.com - April 26 at 11:24 AM
	BRIEF-Conmed Corporation Q1 GAAP Earnings Per Share $0.37 www.reuters.com - April 26 at 9:35 AM
	Conmed Raises FY18 Financial Guidance - Quick Facts www.nasdaq.com - April 26 at 9:35 AM
	CONMED (CNMD) Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 26 at 9:35 AM
	CONMED (CNMD) Releases Earnings Results, Beats Expectations By $0.10 EPS www.americanbankingnews.com - April 25 at 7:46 PM
	CONMED (CNMD) Releases FY18 Earnings Guidance www.americanbankingnews.com - April 25 at 6:28 PM
	Conmed: 1Q Earnings Snapshot www.cnbc.com - April 25 at 4:21 PM
	CONMED Corporation Announces First Quarter 2018 Financial Results finance.yahoo.com - April 25 at 4:21 PM
	Is CONMED Corporation’s (NASDAQ:CNMD) PE Ratio A Signal To Buy For Investors? finance.yahoo.com - April 25 at 10:00 AM
	CONMED Co. (CNMD) Expected to Announce Quarterly Sales of $196.87 Million www.americanbankingnews.com - April 18 at 4:31 AM
	CONMED (CNMD) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 18 at 2:30 AM
	CONMED (CNMD) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - April 17 at 12:47 PM
	Brokerages Expect CONMED Co. (CNMD) to Announce $0.43 EPS www.americanbankingnews.com - April 16 at 5:19 AM
	Needham & Company LLC Boosts CONMED (CNMD) Price Target to $57.00 www.americanbankingnews.com - April 15 at 5:06 PM
	CONMED (CNMD) Downgraded by BidaskClub www.americanbankingnews.com - April 15 at 1:49 PM
	CONMED Co. (CNMD) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 12 at 8:49 AM
	CONMED (CNMD) Upgraded to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 11 at 1:49 PM
	BidaskClub Upgrades CONMED (CNMD) to Sell www.americanbankingnews.com - April 10 at 3:55 PM
	CONMED Corporation to Present at Two Investor Conferences in May finance.yahoo.com - April 5 at 4:10 PM
	CONMED (CNMD) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 4 at 12:57 PM
	Global Surgical Stapling Devices Market Opportunities 2018: Conmed Corporation, Johnson & Johnson, Stryker Corporation www.marketwatch.com - April 3 at 10:10 AM
	$196.87 Million in Sales Expected for CONMED Co. (CNMD) This Quarter www.americanbankingnews.com - April 1 at 4:38 AM
	CONMED (CNMD) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - March 30 at 9:28 PM
	Analysts Expect CONMED Co. (CNMD) Will Post Earnings of $0.43 Per Share www.americanbankingnews.com - March 30 at 9:35 AM
	CONMED (CNMD) Upgraded to Sell at BidaskClub www.americanbankingnews.com - March 30 at 9:27 AM
	FY2018 Earnings Estimate for CONMED Co. (CNMD) Issued By Gabelli www.americanbankingnews.com - March 30 at 7:05 AM
	BidaskClub Upgrades CONMED (CNMD) to Strong-Buy www.americanbankingnews.com - March 27 at 5:10 PM
	CONMED (CNMD) Price Target Increased to $71.00 by Analysts at Needham & Company LLC www.americanbankingnews.com - March 25 at 10:22 PM

CONMED (NASDAQ:CNMD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

CONMED (NASDAQ:CNMD) Income Statement, Balance Sheet and Cash Flow Statement

CONMED (NASDAQ CNMD) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff